Pharma partners

Humabs currently has two clinical-stage partnered programs, validating the CellClone technologies and generating a significant revenue stream

Humabs has a broad partnership with MedImmune, the global biologics research and development arm of AstraZeneca, that covers multiple pathogens. The most advanced of the projects is an antibody directed against influenza A virus.

This antibody, called MEDI8852, has demonstrated activity against all known subtypes of the influenza A virus and is therefore less affected by the emergence of new strains. The program was partnered with MedImmune while still in preclinical development and has currently concluded the clinical phase 1b/2a. Data on this program have been published in the journals Science and Cell. Humabs has also partnered with Novartis for an antibody directed against an undisclosed target. This program is currently in phase 2.

Government and academic partners

Humabs collaborates with government agencies, academic institutions and charitable foundations to advance its programs with the goal of getting them to patients faster.

A good example of these collaborations is for the Company’s antibody against the Ebola virus. Early isolation work was a joint effort with researchers from the US National Institutes of Health (NIH) and the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The antibody is now being manufactured and developed for clinical testing with the support of DARPA. Humabs also collaborates with a variety of academic institutions.

Partnering opportunities

Humabs is seeking development and commercialization partners for several of its development programs:

Dengue virus

JC virus (JCV)

Granulocyte macrophage colony-stimulating factor (GM-CSF)

We welcome inquiries from companies wishing to discuss partnering opportunities.
Business Development & Licensinginfo@humabs.com